Warning: You are not logged in. Your IP address will be recorded in this page's edit history.
These are 29 snps definitely relate to CYP2C9
Here they are:
You are encouraged to leave these fields blank, but hit save below. A bot will fill in everything correctly usually within 24h. If you're in a hurry, please see Template:Gene for a description of the fields.
Here you can edit the Free text: of the page
{{Topic}}[[CYP2C9]] is a member of the IIC subfamily of the cytochrome p450 genes, responsible for metabolizing numerous drugs, such as [[phenytoin]], [[tamoxifen]], [[warfarin]], [[fluvastin]], and many [[nonsteroidal anti-inflammatory drug]]s ([[NSAID]]s) such as [[aspirin]], [[ibuprofen]] and [[naproxen]]. People who carry [[CYP2C9]] variants may process such drugs differently. SNPs in [[CYP2C9]] include: * [[rs1057910]]; two variants encode the CYP2C9*1 and CYP2C9*3 alleles * [[rs1799853]], versions of which encode CYP2C9*2 alleles A recent [http://www.fda.gov/bbs/topics/NEWS/2007/NEW01684.html FDA action] stipulates that the possibility of genetic testing for SNPs in the CYP2C9 gene be included on the label for the medicine known as [[warfarin]] (trade name [[Coumadin]]). [[Plavix]], the trade name for [[clopidogrel]], is a drug commonly prescribed to reduce the chance of a type of [[heart disease]] (acute coronary syndrome), and it inhibits [[CYP2C9]] at high enough doses. This may therefore interfere with the metabolism of drugs processed by [[CYP2C9]], and individuals with [[CYP2C9]] SNP variants that encode lower metabolizers to begin with would presumably be at greater risk for such side-effects when taking [[Plavix]] at the same time as drugs metabolized by [[CYP2C9]]. A more detailed list of [[CYP2C9]] SNPs includes: {| class="wikitable" |- ! Allele Name ! Defining Name/Change ! Rs# ! Comments ! Enzyme Activity ! Platforms |- | CYP2C9*1 | | | Wild-type | normal | |- | CYP2C9*2 | 430C>T | [[rs1799853]] | R144C | inactive | {{#show:Rs1799853|?On microarray}} |- | CYP2C9*3 | 1075A>C | [[rs1057910]] | I359L | inactive | {{#show:Rs1057910|?On microarray}} |- | CYP2C9*4 | 1076T>C | [[rs56165452]] | I359T | decreased | {{#show:Rs56165452|?On microarray}} |- | CYP2C9*5 | 1080C>G | [[rs28371686]] | D360E | decreased | {{#show:Rs28371686|?On microarray}} |- | CYP2C9*6 | 818delA | [[rs9332131]] | 273frameshift | inactive | {{#show:Rs9332131|?On microarray}} |- | CYP2C9*7 | 55C>A | [[rs67807361]] | L19I | | {{#show:Rs67807361|?On microarray}} |- | CYP2C9*8 | 449G>A | [[rs7900194]] | R150H | decreased | {{#show:Rs7900194|?On microarray}} |- | CYP2C9*9 | 752A>G | [[rs2256871]] | H251R | | {{#show:Rs2256871|?On microarray}} |- | CYP2C9*10 | 815A>G | [[rs9332130]] | E272G | | {{#show:Rs9332130|?On microarray}} |- | CYP2C9*11 | 1003C>T | [[rs28371685]] | R335W | decreased | {{#show:Rs28371685|?On microarray}} |- | CYP2C9*12 | 1465C>T | [[rs9332239]] | P489S | | {{#show:Rs9332239|?On microarray}} |- | CYP2C9*13 | 269T>C | [[rs72558187]] | L90P | decreased | {{#show:Rs3892097|?On microarray}} |- | CYP2C9*14 | 374G>A | [[rs72558189]] | R125H | | {{#show:Rs72558189|?On microarray}} |- | CYP2C9*15 | 485C>A | [[rs72558190]] | S162X | inactive | {{#show:Rs72558190|?On microarray}} |- | CYP2C9*25 | 353_362delAGAAATGGAA | [[rs72558188]] | 118frameshift | inactive | {{#show:Rs72558188|?On microarray}} |- | CYP2C9_42612A>G | 42612A>G | [[rs1057909]] | Y358C | | {{#show:Rs1057909|?On microarray}} |- | CYP2C9_50196C>T | 50196C>T | [[rs2017319]] | A441A | | {{#show:Rs2017319|?On microarray}} |- | CYP2C9_50298A>T | 50298A>T | [[rs1057911]] | G475G | | {{#show:Rs3892097|?On microarray}} |- |} In one of the largest "negative" studies reported to date, three independent studies totaling over 52,000 individuals found no association between CYP2C9 polymorphisms (specifically, the *2 and *3 alleles) and risk of subclinical atherosclerosis, ischemic vascular disease or death after ischemic heart disease.[PMID 19652664]
Summary:
This is a minor edit Watch this page
Cancel
